Cargando…

Vascular Complications in Patients with Hepatocellular Carcinoma Treated with Sorafenib

SIMPLE SUMMARY: Inhibition of vascular endothelial growth factor receptor (VEGFR) signaling is associated with an increased risk of thromboembolic and bleeding complications in cancer patients and may cause fatal side effects. The multityrosine kinase inhibitor sorafenib represents an important trea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pomej, Katharina, Scheiner, Bernhard, Park, Dabin, Bauer, David, Balcar, Lorenz, Meischl, Tobias, Mandorfer, Mattias, Reiberger, Thomas, Müller, Christian, Trauner, Michael, Pinter, Matthias
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7602103/ https://www.ncbi.nlm.nih.gov/pubmed/33066190 http://dx.doi.org/10.3390/cancers12102961

Ejemplares similares

Antibiotic Therapy is Associated with Worse Outcome in Patients with Hepatocellular Carcinoma Treated with Sorafenib
por: Pomej, Katharina, et al.
Publicado: (2021)

Early changes in immunoglobulin G levels during immune checkpoint inhibitor treatment are associated with survival in hepatocellular carcinoma patients
por: Balcar, Lorenz, et al.
Publicado: (2023)

COVID-19 pandemic: Impact on the management of patients with hepatocellular carcinoma at a tertiary care hospital
por: Pomej, Katharina, et al.
Publicado: (2021)

Patterns of acute decompensation in hospitalized patients with cirrhosis and course of acute‐on‐chronic liver failure
por: Balcar, Lorenz, et al.
Publicado: (2021)

Safety of direct oral anticoagulants in patients with advanced liver disease
por: Semmler, Georg, et al.
Publicado: (2021)

Transversal psoas muscle thickness measurement is associated with response and survival in patients with HCC undergoing immunotherapy
por: Scheiner, Bernhard, et al.
Publicado: (2023)

COVID‐19‐Related Downscaling of In‐Hospital Liver Care Decreased Patient Satisfaction and Increased Liver‐Related Mortality
por: Hartl, Lukas, et al.
Publicado: (2021)

Imaging features facilitate diagnosis of porto-sinusoidal vascular disorder
por: Lampichler, Katharina, et al.
Publicado: (2022)

Short- and long-term effects of transarterial chemoembolization on portal hypertension in patients with hepatocellular carcinoma
por: Scheiner, Bernhard, et al.
Publicado: (2019)

Impact of ammonia levels on outcome in clinically stable outpatients with advanced chronic liver disease
por: Balcar, Lorenz, et al.
Publicado: (2023)

Alpha‐fetoprotein‐adjusted‐to‐HCC‐size criteria are associated with favourable survival after liver transplantation for hepatocellular carcinoma
por: Meischl, Tobias, et al.
Publicado: (2021)

Alpha-1 antitrypsin Pi∗Z allele is an independent risk factor for liver transplantation and death in patients with advanced chronic liver disease
por: Balcar, Lorenz, et al.
Publicado: (2022)

An impaired pituitary–adrenal signalling axis in stable cirrhosis is linked to worse prognosis
por: Hartl, Lukas, et al.
Publicado: (2023)

Clinical characteristics and outcome of patients with combined hepatocellular-cholangiocarcinoma—a European multicenter cohort
por: Pomej, K., et al.
Publicado: (2023)

C-reactive protein is an independent predictor for hepatocellular carcinoma recurrence after liver transplantation
por: Meischl, Tobias, et al.
Publicado: (2019)

Impact of farnesoid X receptor single nucleotide polymorphisms on hepatic decompensation and mortality in cirrhotic patients with portal hypertension
por: Semmler, Georg, et al.
Publicado: (2019)

Distinct prognostic value of different portal hypertension-associated features in patients with primary biliary cholangitis
por: Burghart, Lukas, et al.
Publicado: (2021)

Performance of Controlled Attenuation Parameter in Patients with Advanced Chronic Liver Disease and Portal Hypertension
por: Semmler, Georg, et al.
Publicado: (2019)

Portal hypertensive gastropathy is associated with iron deficiency anemia
por: Simbrunner, Benedikt, et al.
Publicado: (2020)

Guideline-conform statin use reduces overall mortality in patients with compensated liver disease
por: Unger, Lukas W., et al.
Publicado: (2019)

Non‐invasive detection of portal hypertension by enhanced liver fibrosis score in patients with different aetiologies of advanced chronic liver disease
por: Simbrunner, Benedikt, et al.
Publicado: (2020)

Patterns and prevalence of dyslipidemia in patients with different etiologies of chronic liver disease
por: Unger, Lukas W., et al.
Publicado: (2019)

Prevalence of and risk factors for anaemia in patients with advanced chronic liver disease
por: Scheiner, Bernhard, et al.
Publicado: (2019)

Vitamin A levels reflect disease severity and portal hypertension in patients with cirrhosis
por: Simbrunner, Benedikt, et al.
Publicado: (2020)

Hepatic Steatosis in Lean Patients: Risk Factors and Impact on Mortality
por: Unger, Lukas W., et al.
Publicado: (2019)

Eligibility for antiviral therapy and treatment uptake in chronic hepatitis B patients referred to a European tertiary care center
por: Jachs, Mathias, et al.
Publicado: (2023)

Influence of Genetic Variants on Disease Regression and Outcomes in HCV-Related Advanced Chronic Liver Disease after SVR
por: Semmler, Georg, et al.
Publicado: (2021)

Gut-liver axis signaling in portal hypertension
por: Simbrunner, Benedikt, et al.
Publicado: (2019)

Recent advances in the understanding and management of hepatorenal syndrome
por: Simbrunner, Benedikt, et al.
Publicado: (2021)

Renin/angiotensin system-coagulation-inflammation axis abnormalities: a possible explanation for susceptibility to severe COVID-19 in cirrhosis
por: Hartl, Lukas, et al.
Publicado: (2022)

Targeting DNA repair to enhance the efficacy of sorafenib in hepatocellular carcinoma
por: Samadaei, Mahzeiar, et al.
Publicado: (2022)

Interferon-free regimens improve health-related quality of life and fatigue in HIV/HCV-coinfected patients with advanced liver disease: A retrospective study
por: Scheiner, Bernhard, et al.
Publicado: (2016)

Progress in eradication of HCV in HIV positive patients with significant liver fibrosis in Vienna
por: Steiner, Sebastian, et al.
Publicado: (2017)

Cirrhosis-Associated RAS-Inflammation-Coagulation Axis Anomalies: Parallels to Severe COVID-19
por: Hartl, Lukas, et al.
Publicado: (2021)

Bacterial translocation occurs early in cirrhosis and triggers a selective inflammatory response
por: Simbrunner, Benedikt, et al.
Publicado: (2023)

Impact of HSD17B13 rs72613567 genotype on hepatic decompensation and mortality in patients with portal hypertension
por: Scheiner, Bernhard, et al.
Publicado: (2019)

Covered Transjugular Intrahepatic Portosystemic Shunt Improves Hypersplenism-Associated Cytopenia in Cirrhosis
por: Bucsics, Theresa, et al.
Publicado: (2022)

Von Willebrand factor processing in patients with advanced chronic liver disease and its relation to portal hypertension and clinical outcome
por: Simbrunner, Benedikt, et al.
Publicado: (2023)

Controlled attenuation parameter does not predict hepatic decompensation in patients with advanced chronic liver disease
por: Scheiner, Bernhard, et al.
Publicado: (2018)

The impact of hepatic steatosis on portal hypertension
por: Semmler, Georg, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_qhqaan63cbt80ll8qt330lcoep